Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
Vanderbilt epidemiologists identified new markers for colorectal cancer risk and characterized a previously unidentified tumor suppressor that regulates overall tumor volume in vivo.
A new method that keeps microbes and gut cells together will be useful for studies of complex host-microbe interactions and for analysis of clinical specimens.
It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.
Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.
Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.